- CEO
- Ery Yunasri
- Full Time Employees
- 2,305
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Jl. Rawa Sumur II Kav. BB No. 3 Jakarta JKT Indonesia 13930
- IPO Date
- Sep 8, 2020
- Business
- PT Soho Global Health Tbk (SOHO.JK) operates as an integrated healthcare company in Indonesia, focusing on the research, development, manufacturing, and distribution of herbal-based medicines and related health products. The company offers a portfolio of nonprescription consumer health brands including Imboost and Imboost Force for immune support, Curcuma Plus Milk and Multivitamins for child nutrition and growth, Diapet for digestive health, Fitkom children's multivitamins, Curcuma Group for liver function and appetite enhancement, Lelap, Asthma Soho, Sohobion, and Asthin antioxidants; it also provides contract manufacturing services across various dosage forms, distribution and logistics through subsidiary PT Parit Padang Global, medical devices in wound care, orthopedics, surgery, and in-vitro diagnostics, alliance and in-licensing partnerships for multinational products, product registration, marketing intelligence, and sales support services. PT Soho Global Health Tbk serves segments encompassing Distribution, Professional Products, Consumer Health, Alliance, and Others, targeting healthcare professionals, pharmacies, hospitals, and general consumers primarily in Indonesia with selective ASEAN presence.
Founded in 1946 and headquartered in Jakarta, Indonesia, the company maintains operations centered in the domestic market while leveraging global research collaborations such as with Soho Flordis International for natural ingredient development.
Recent developments include multiple distribution partnership expansions by subsidiary PT Parit Padang Global, such as agreements signed in January 2025 with PT Mitra Mas Sentosa for Cool-Vita vitamin supplements, in April 2025 with PT Ichiya Indonesia for Okamoto branded products, and additional collaborations with PT Sea Makeup Beauty for The Originote and others in 2025; further, a June 2025 memorandum of understanding with RSUP Dr. Sardjito establishes strategic ties in education, research, and pharmaceuticals.